EZR

Across TCGA pan-cancer cohorts, EZR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EZR data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EZR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EZR expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where EZR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.281	0.552	.002	22	view →
CCRCC	DFS	Quartile	III,IV	1.000	0.741	.017	15	view →
GBM	OS	Tertile	All	0.231	0.597	.009	13	view →
LSCC	OS	Quartile	II,III,IV	0.588	0.917	.030	8	view →
HNSC	DFS	Tertile	II,III,IV	0.980	0.873	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EZR–PDAC (DFS)

Open the PDAC breakdown →